Interpace Biosciences, Inc. (IDXG)
| Previous Close | 1.4500 |
| Open | 1.4300 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 1.4290 - 1.4500 |
| 52 Week Range | 0.6203 - 3.5400 |
| Volume | |
| Avg. Volume | 5,659 |
| Market Cap | 6.346M |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 5.80 |
| EPS (TTM) | 0.2500 |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireInterpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and 119% increase year-over-year ●Q4 and FY Adjusted EBITDA of $1.5 million and $5.4 million; a $6.6 million and 463% increase year-over-year ●Q4 and FY Cash collections of $10.2 million and $40.4 million; a $9.0 million and 29% increase year-over-year ●Q4 and FY Volume, Revenue, and Profitability at al
- GlobeNewswire
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update. Third quarter Net Revenue was
- GlobeNewswire
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financia
